BMS awarded 2018 ENERGY STAR Partner of the Year Sustained Excellence Award
The company’s environmental efforts honored for the fourth consecutive year.
The US Environmental Protection Agency (EPA) and the US Department of Energy have recognized Bristol-Myers Squibb (BMS) with an ENERGY STAR Partner of the Year Sustained Excellence Award for outstanding efforts to improve the energy efficiency of facilities worldwide. BMS has earned the ENERGY STAR Partner of the Year award for the past 4 consecutive years.
The award confirms BMS’s long-term commitment to environmental responsibility through driving sustainable improvements in energy with a goal of reducing the company use or resources across its drug discovery, development and delivery pipeline.
“We are proud to receive the ENERGY STAR Partner of the Year designation for 4 years, and to increase our recognition with the Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, BMS. “To continue developing innovative medicines for our patients, we have to embrace our responsibility to support our environment, employees and communities. We look forward to our continued partnership with ENERGY STAR to better advance our energy management programs and demonstrate our leadership within the pharmaceutical industry.”
BMS was recognized for the following accomplishments:In addition to the company’s recognition as an ENERGY STAR Partner of the Year, BMS’s R&D site in Hopewell, New Jersey, and the manufacturing site in New Brunswick, New Jersey earned the 2017 Challenge for Industry recognition. The ENERGY STAR Challenge for Industry is a national call-to-action to improve energy efficiency of America’s manufacturers by 10% or more. By taking the ENERGY STAR Challenge, sites set a goal to reduce their energy intensity by 10% within 5 years.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.